Vaidyanathan B, Menon P S
Department of Pediatrics, All India Institute of Medical Sciences, New Delhi.
Indian J Pediatr. 2000 Jun;67(6):435-41. doi: 10.1007/BF02859462.
The introduction of insulin analogues, of which insulin lispro is the prototype, marks a very important milestone in the management of patients with diabetes mellitus. It differs from regular human insulin in its quicker onset and shorter duration of action. In various clinical trials, insulin lispro was found to be superior to regular human insulin in controlling postprandial hyperglycemia without increasing the risk of hypoglycemia. It improved the quality of life of diabetic patients by providing more flexibility to meal plans. Recently, another short acting insulin analogue called insulin aspart has been tried in clinical studies with benefits similar to insulin lispro. The turn of the millennium is now witnessing the development of long acting insulin analogues like insulin glargine, which can provide continuous low-level basal insulin concentrations similar to natural settings. In this review, we discuss the potential of insulin analogues in the modern management of diabetes with emphasis on insulin lispro.
胰岛素类似物的引入,其中赖脯胰岛素是原型药物,标志着糖尿病患者管理方面的一个非常重要的里程碑。它与常规人胰岛素的不同之处在于起效更快、作用持续时间更短。在各种临床试验中,发现赖脯胰岛素在控制餐后高血糖方面优于常规人胰岛素,且不增加低血糖风险。它通过为饮食计划提供更大的灵活性,改善了糖尿病患者的生活质量。最近,另一种名为门冬胰岛素的短效胰岛素类似物已在临床研究中进行试验,其益处与赖脯胰岛素相似。千年之交正见证着甘精胰岛素等长效胰岛素类似物的发展,它能提供与自然状态相似的持续低水平基础胰岛素浓度。在本综述中,我们讨论胰岛素类似物在现代糖尿病管理中的潜力,重点是赖脯胰岛素。